• A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension

  NCT00522925

  CompletedInterventionalPhase 2Updated Sep 16, 2011
• A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure

  NCT00422461

  CompletedInterventionalPhase 2Updated Oct 11, 2021
• Food Supplementation With Diuripres for Blood Pressure Modulation in Subjects With High-Normal Blood Pressure

  NCT05167747

  CompletedInterventionalNot ApplicableUpdated Feb 1, 2024
• The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED)

  NCT01130168

  CompletedInterventionalPhase 1Updated Oct 9, 2015
• A Study to Investigate the Effect of a Nitric Oxide Supplementation on Pre- and Mildly Hypertensive Adults

  NCT02679248

  TerminatedInterventionalPhase 2Updated Apr 12, 2018
• Nutraceutical Supplement in the Management of Hypertension

  NCT02663479

  CompletedInterventionalPhase 1Phase 2Updated Mar 13, 2020

ClinicalTrials.gov ID

NCT07629570

Lead Sponsor

Eetho Brands, IncINDUSTRY

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

198Estimated

Last Update Posted

Jun 5, 2026Actual

Start Date

May 15, 2026Estimated

Primary Completion Date

Jul 30, 2026Estimated

Completion Date

Aug 30, 2026Estimated

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of DOSE for Blood Pressure Shot (DBPS) in Prehypertensive Subjects.

Brief Summary

Prehypertension is a clinical condition characterized by systolic blood pressure (SBP) readings between 120 and 139 mmHg and/or diastolic blood pressure (DBP) readings between 80 and 89 mmHg, as per the Joint National Committee (JNC 7) and World Health Organization (WHO) guidelines. Individuals falling within this range do not yet meet the criteria for hypertension but are at a significantly elevated risk of progressing to full-blown hypertension and developing associated cardiovascular diseases such as heart attack and stroke. This stage is considered as a critical window for intervention, as timely and appropriate measures can potentially halt or delay the progression to more severe health issues.

Detailed Description

This is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effectiveness of 4-week supplementation regimen of 'DOSE for Blood Pressure Shot (DBPS)' in reducing systolic and diastolic blood pressure among prehypertensive adults. DBPS is formulated as a liquid oral supplement specifically designed to support cardiovascular wellbeing. The product is rooted in both preliminary scientific evidence and traditional medicinal practices, which indicate that it may exert blood-pressure lowering effects by influencing vascular tone and modulating inflammatory pathways within the body. The active ingredients in DBPS are believed to help relax blood vessels, improve endothelial function, and reduce systemic inflammation, all of which contribute to healthier blood pressure levels.

• Prehypertension

• DBPS
• Placebo

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

Yes

Eligibility Criteria

Inclusion Criteria:

1. Men and women between the ages 18 and 65 years, inclusive, at the time of signing the informed consent.
2. Seated clinic systolic blood pressure (SBP) in the range of 120 to 139 mm Hg and diastolic blood pressure (DBP) in the range of 80 to 89 mmHg confirming a prehypertensive state as per JNC 7 and WHO guidelines.
3. In good general health as determined by a medical history, physical examination, vital signs, electrocardiogram (ECG), and routine clinical laboratory tests (hematology, clinical chemistry, urinalysis).
4. Body Mass Index less than 30 kg/m2.
5. Women of childbearing potential (WOCBP) must agree to use a highly effective method of contraception (e.g., oral contraceptives, intrauterine device, barrier methods with spermicide, surgical sterilization) from screening until the end of the study. Women who are postmenopausal (defined as amenorrhea for at least 12 consecutive months) or surgically sterile are eligible.
6. Provide written informed consent to participate in the study after all procedures have been fully explained and questions answered.
7. Willing and able to comply with all study procedures, visit schedules, and restrictions.

Exclusion Criteria:

1. Diagnosed with Stage 1 Hypertension (SBP more than 139 mmHg or DBP more than 89 mmHg or Stage 2 Hypertension as per JNC 7 and WHO guidelines

2. Evidence of secondary hypertension (e.g., renal artery stenosis, primary hyperaldosteronism, sleep apnea).

3. History of significant cardiovascular disease, including but not limited to:

   (i) Myocardial infarction, stroke, or transient ischemic attack within the past 6 months.

   (ii) Symptomatic heart failure or left ventricular ejection fraction less than 40%.

   (iii) Cases of class III and class IV congestive heart failure (CHF) as defined by the New York Heart Association.

   (iv) Unstable angina pectoris or revascularization procedure within the past 3 months.

   (v) Significant valvular heart disease or complex congenital heart disease by medical history.

4. Use of any medications (prescription, over-the-counter, herbal supplements, certain vitamins/minerals) known to affect blood pressure or interfere with study product absorption/metabolism within 14 days prior to the dosing visit, or unwillingness to stop them for the study duration.

5. Organ Function Impairment:

   (i)Impaired hepatic function (Alanine aminotransferase [ALT] or Aspartate aminotransferase more tan 2 times the upper limit of normal [ULN]).

   (ii)Impaired renal function (serum creatinine level more than 132.6 μmol/L or estimated Glomerular Filtration Rate [eGFR] less than 60 mL/min/1.73m2).

   (iii) Serum potassium outside the normal range (less than 3.5 mmol/L or more than 5.5 mmol/L).

6. History of uncontrolled diabetes mellitus (e.g., HbA1C level more than 7.0% and/or FBS more than 125mg/dL or use of diabetes medications).

7. Any chronic diseases that may interfere with study participation or pose additional risk to the subject.

8. A tobacco smoker or user of nicotine products in the 6 months prior to screening.

9. Excessive alcohol consumption (Men more than 14 drinks/week and women more than 7 drinks/week).

10. History of substance abuse or dependency within the last 1 year.

11. Women who are pregnant or lactating.

12. History of hypersensitivity or contraindication to the test product (DBPS) or any of its components or placebo.

13. Participation in another clinical research study involving an investigational product within 30 days prior to screening or during the current study.

Primary Purpose

Prevention

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Triple

Lead Sponsor

Eetho Brands, IncINDUSTRY

harsh656@gmail.com+91-9793036567

manojsrivastava39@yahoo.in+91-0542-2281750

raghvendras069@gmail.com+91-8765548689